Colchicine for acute gout

Cochrane Database of Systematic Reviews

Volumn 2014, Issue 8, 2014, Pages

  van Echteld, Irene ^a   Wechalekar, Mihir D ^b   Schlesinger, Naomi ^c   Buchbinder, Rachelle ^d   Aletaha, Daniel ^e  

^a CPRLab   (Netherlands)

^b REPATRIATION GENERAL HOSPITAL   (Australia)

^c ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^d MONASH UNIVERSITY   (Australia)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

COLCHICINE; PLACEBO; ANTIGOUT AGENT;

ADVERSE EVENT; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONTROLLED CLINICAL TRIAL (TOPIC); COST BENEFIT ANALYSIS; DIARRHEA; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; ERYTHEMA; GASTROINTESTINAL SYMPTOM; GOUT; HEALTH HAZARD; HUMAN; LOW DRUG DOSE; NAUSEA; OUTCOME ASSESSMENT; PAIN ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; SWELLING; SYSTEMATIC REVIEW; VOMITING; ANALGESIA; META ANALYSIS; METHODOLOGY; TIME;

COLCHICINE; GOUT; GOUT SUPPRESSANTS; HUMANS; PAIN MANAGEMENT; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS;

EID: 84907213596     PISSN: 14651858     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD006190.pub2     Document Type: Review

References (49)

1. Ahern MJ, Reid C, Gordon TP. Does colchicine work? Results of the first controlled study in gout. Australian and New Zealand Journal of Medicine 1987;17:301-4.
2. Furst D, Maranian E, Davis P, Wason MW, Khanna S, Terkeltaub D. Chronologic age, renal function, and comorbid conditions (physiologic age) of patients with gout did not increase likelihood of adverse events (AEs): AGREE study post hoc analyses. Arthritis and Rheumatism 2009;62(Suppl 10):147.
3. Terkeltaub R, Furst D, Bennett E, Kook K, Crockett K, Davis RS, et al.Colchicine efficacy assessed by time to 50 reduction of pain is comparable in low dose and high dose regimens: secondary analyses of the agree trial. Arthritis and Rheumatism 2010;60(Suppl 10):1103.
4. Terkeltaub RA, Furst DE, Bennett K, Kook KA, Crockett RS, Davis MW. High versus low dosing of oral colchicine for early acute gout flare: twenty-four-hour outcome of the first multicenter, randomised, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis and Rheumatism 2010;62:1060-8.
5. Schlesinger N, Baker DG, Beutler AM, Hoffman BI, Schumacher Hr, Jr. Local ice therapy during bouts of acute gouty arthritis. Journal of Rheumatology 2002;29(2):331-4.
6. Agudelo CA, Schumacher HR Jr, Phelps P. Effect of exercise on urate crystal-induced inflammation in canine joints. Arthritis and Rheumatism 1972;15:609-16.
7. Arnold MH, Preston SJ, Buchanan WW. Comparison of the natural history of untreated acute gouty arthritis vs acute gouty arthritis treated with non-steroidal-anti-inflammatory drugs. British Journal of Clinical Pharmacology 1988;26:488-9.
8. Atkins D, Best D, Briss PA, Eccles M, Palck-Ytter Y, Flottorp S, et al.GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ 2004;328(7454):1490-4.
9. Australian Rheumatology Association. Patient information on colchicine (last updated November 2012). http://www.rheumatology.org.au (accessed 3 December 2013).
10. Bellamy N, Downie WW, Buchanan WW. Observations on spontaneous improvement in patients with podagra: implications for therapeutic trials of non-steroidal anti-inflammatory drugs. British Journal of Clinical Pharmacology 1987;24(1):33-6.
11. Ben-Chetrit E, Levy M. Colchicine: 1998 update. Seminars in Arthritis and Rheumatism 1998;28:48-59.
12. British National Formulary. http://bnf.org/bnf/bnf/current/search.htm?n=50&q=colchicine+gout (accessed 10 August 2006).
13. Boutron I, Moher D, Altman DG, Schulz K, Ravaud P, CONSORT Group. Methods and processes of the CONSORT Group: example of an extension for trials assessing nonpharmacologic treatments. Annals of Internal Medicine 2008;148:295-309.
14. Dr. Chris Cates' EBM website. URL: http://www.nntoline.net. Visual Rx Version 3. Dr. Chris Cates' EBM website. URL: http://www.nntoline.net, 2008.
15. Cox AR. Colchicine in acute gout: optimal dose of colchicine is still elusive. BMJ 2004;328(7434):288.
16. De Angelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, et al.Clinical Trial Registration: a statement from the International Committee of Medical Journal Editors. JAMA 2004;292(11):1363-4.
17. Deeks JJ, Higgins JPT, Altman DG. Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
18. Dorwart BB, Hansell JR, Schumacher HR Jr. Effects of cold and heat on urate-induced synovitis in the dog. Arthritis and Rheumatism 1974;17(5):563-71.
19. Grainger R, Taylor WJ, Dalbeth N, Perez-Ruiz F, Singh JA, Waltrip RW, et al.Progress in measurement instruments for acute and chronic gout studies. Journal of Rheumatology 2009;36(10):2346-55.
20. Hak AE, Curhan GC, Grodstein F, Choi HK. Menopause, postmenopausal hormone use and risk of incident gout. Annals of the Rheumatic Diseases 2010;69(7):1305-9.
21. Hamburger M, Baraf HS, Adamson TC, Basile J, Bass L, Cole B, et al.2011 recommendations for the diagnosis and management of gout and hyperuricemia. Physician and Sportsmedicine 2011;39(4):98-123.
22. Higgins JPT, Altman DG, Sterne JAC. Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
23. Higgins JPT, Deeks JJ, Altman DG. Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
24. Higgins JPT, Deeks JJ. Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
25. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
26. Janssens HJ, Janssen M, Van de Lisdonk EH, Van Riel PL, Van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60.
27. Janssens HJ, Lucassen PL, Van de Laar FA, Janssen M, Van de Lisdonk EH. Systemic corticosteroids for acute gout. Cochrane Database of Systematic Reviews 2008, Issue 2. [DOI: 10.1002/14651858.CD005521.pub2]
28. Kasper DL, Braunwald E, Fauci AS, Hauser SL, Longo DL, Jameson DL, et al.Harrison's Principles of Internal Medicine. 16th Edition. McGraw-Hill Professional, 2005.
29. Kuncl R, Duncan G, Watson D, Alderson K, Rogawski MA, Peper M. Colchicine myopathy and neuropathy. New England Journal of Medicine 1987;316(25):1562-8.
30. Mikuls TR, Farrar JT, Fernandes S, Schumacher HR Jr, Saag KG. Gout epidemiology: results from the UK General Practice Research Database, 1990-1999. Annals of the Rheumatic Diseases 2005;64:267-72.
31. Moi JHY, Sriranganathan MK, Edwards CJ, Buchbinder R. Lifestyle interventions for chronic gout. Cochrane Database of Systematic Reviews 2013, Issue 5. [DOI: 10.1002/14651858.CD010039.pub2]
32. Morris I, Varughese G, Mattingly P. Colchicine in acute gout. BMJ 2003;327(7426):1275-6.
33. O'Sullivan JB. Gout in a New England Town. A prevalence study in Sudbury, Massachusetts. Annals of the Rheumatic Diseases 1972;31(3):166-9.
34. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager. 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
35. Schlesinger N, Schumacher Jr HR. Gout: can management be improved?. Current Opinion in Rheumatology 2001;13(3):240-4.
36. Schlesinger N. Management of acute and chronic gouty arthritis: present state-of-the-art. Drugs 2004;64(21):2399-416.
37. Schumacher H, Klippel J, Koopman W, et al.Primer on the Rheumatic Diseases. Tenth. Arthritis Foundation, 1993.
38. Schumacher HR, Edwards LN, Perez-Ruiz F, Becker M, Chen LX, Furst DE. Outcome measures for acute and chronic gout. Journal of Rheumatology 2005;32(12):2452-5.
39. Schünemann HJ, Oxman AD, Higgins JPT, Vist GE, Glasziou P, Guyatt GH. Chapter 11: Presenting results and 'Summary of findings' tables. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
40. Singh JA, Taylor WJ, Simon LS, Khanna PP, Stamp LK, McQueen FM, et al.Patient-reported outcomes in chronic gout: a report from OMERACT 10. Journal of Rheumatology 2011;38:1452-7.
41. Sivagnanam G. Colchicine in acute gout: low dose colchicine was started after usual dose. BMJ 2004;328(7434):288-9.
42. Sterne JAC, Egger M, Moher D. Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
43. Tugwell P, Shea B, Boers M, Brooks P, Simon LS, Strand V, et al.Evidence-Based Rheumatology. BMJ Books, 2004.
44. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu T-F. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis and Rheumatism 1977;20:895-900.
45. Wallace SL, Singer JZ. Therapy in gout. Rheumatic Diseases Clinics of North America 1988;14:441-57.
46. Wechalekar MD, Vinik O, Schlesinger N, Buchbinder R. Intra-articular glucocorticoids for acute gout. Cochrane Database of Systematic Reviews 2013, Issue 4. [DOI: 10.1002/14651858.CD009920.pub2]
47. Wortmann RL. Gout and hyperuricemia. Current Opinion in Rheumatology 2002;14:281-6.
48. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al.EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Annals of the Rheumatic Diseases 2006;65(10):1312-24.
49. Schlesinger N, Schumacher R, Catton M, Maxwell L. Colchicine for acute gout. Cochrane Database of Systematic Reviews 2006, Issue 4. [DOI: 10.1002/14651858.CD006190]